20159 ⎘
Medicinal preparations characterised by special physical form; Preparations in capsules, e.g. of gelatin, of chocolate; Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
Sub-classes:METHOD FOR DRYING FECAL MICROBIOTA MULTILAYER DRIPPING PILLS
#2Particles Containing a Lipid Matrix Core and Active Ingredient
#3SOLID NANOPARTICLE WITH INORGANIC COATING
#4MULTILAYERED PHARMACEUTICALLY ACTIVE COMPOUND-RELEASING MICROPARTICLES IN A LIQUID DOSAGE FORM
#5METHYLPHENIDATE MODIFIED RELEASE FORMULATIONS
#6COMPOSITIONS AND METHODS FOR TREATING VENOUS BLOOD CLOTS
#7Implantable Device for Sustained Release of a Macromolecular Drug Compound
#8Dry Powdered Formulations
#9MUCO-ADHESIVE, CONTROLLED RELEASE FORMULATION OF LEVODOPA AND/OR ESTERS OF LEVODOPA AND USES THEREOF
#10Compositions for Treatment of Attention Deficit Hyperactivity Disorder
#11METHODS AND COMPOSITIONS PARTICULARLY FOR TREATMENT OF ATTENTION DEFICIT DISORDER
#12Modified Release Formulations of 2-[3-[4-Amino-3-(2-Fluoro-4-Phenoxy-Phenyl) Pyrazolo[3,4-D] Pyrimidin-1-yl]Piperidine-1-Carbonyl]-4-Methyl -4-[4-(Oxetan-3-yl)Piperazin-1-yl]Pent-2-Enenitrile
#13Method for preparing SAMe microcapsules
#14Phloroglucinol Formulations And Methods Of Use
#15DOUBLE-LAYER COATED MICROPARTICLES AND PREPARATION THEREOF
#16MUCO-ADHESIVE, CONTROLLED RELEASE FORMULATION OF LEVODOPA AND/OR ESTERS OF LEVODOPA AND USES THEREOF
#17METHOD FOR PREPARING MICROCAPSULE, MICROCAPSULE AND COMPOSITION CONTAINING THE SAME
#18IMPLANTABLE PARTICLES AND RELATED METHODS
#19COMPOSITIONS AND METHODS FOR TREATING MULTIPLE SCLEROSIS
#20MUCO-ADHESIVE, CONTROLLED RELEASE FORMULATION OF LEVODOPA AND/OR ESTERS OF LEVODOPA AND USES THEREOF
#21Muco-adhesive, controlled release formulation of levodopa and/or esters of levodopa and uses thereof
#22Intestine-Targeted Drug Delivery Compositions and Preparation Methods Thereof
#23Muco-adhesive, controlled release formulation of levodopa and/or esters of levodopa and uses thereof
#24Dry Powdered Formulations
#25COATED ACTIVE INGREDIENT FORMULATION FOR CONTROLLED IN-VIVO UPTAKE OF CO2
#26Muco-adhesive, controlled release formulation of levodopa and/or esters of levodopa and uses thereof
#27COMPOSITIONS, DEVICES AND METHODS FOR INDUCING ANTIGEN-SPECIFIC IMMUNE TOLERANCE
#28Formulations and Pharmacokinetics of Deuterated Benzoquinoline Inhibitors of Vesicular Monoamine Transporter 2
#29Muco-adhesive, controlled release formulations of levodopa and/or esters of levodopa and uses thereof
#30Obizidine Fumarate Enteric-coated Pellets, and preparation and use thereof
#31MODIFIED RELEASE COMPOSITION OF ORLISTAT AND ACARBOSE FOR THE TREATMENT OF OBESITY AND RELATED METABOLIC DISORDERS
#32Extended-release compositions comprising atomoxetine
#33Extended release compositions comprising pyridostigmine
#34SHELF STABLE ORGANIC NUCLEOTIDE COMPOSITIONS AND METHODS OF MANUFACTURING THE SAME
#35NEW FORMULATIONS COMPRISING AZACITIDINE
#36NEW FORMULATIONS COMPRISING BIOLOGIC ACTIVE DRUGS
#37METHODS AND COMPOSITIONS PARTICULARLY FOR TREATMENT OF ATTENTION DEFICIT DISORDER
#38Implantable Device for Sustained Release of a Macromolecular Drug Compound
#39LAYERED PARTICLES AND PROCESSES THEREOF
#40Compositions for Treatment of Attention Deficit Hyperactivity Disorder
#41GAMMA-HYDROXYBUTYRATE FORMULATIONS HAVING IMPROVED STABILITY AFTER STORAGE
#42Modified Release Formulations of 2-[3-[4-Amino-3-(2-Fluoro-4-Phenoxy-Phenyl) Pyrazolo[3,4-D] Pyrimidin-1-YL]Piperidine-1-Carbonyl]-4-Methyl -4-[4-(Oxetan-3-YL)Piperazin-1-YL]Pent-2-Enenitrile
#43HIGH TEMPERATURE RESISTANT PROBIOTICS FOR FOOD OR BEVERAGE AND METHOD OF MAKING THE SAME
#44ORAL AMPHETAMINE COMPOSITION
#45COMPOSITION COMPRISING OIL DROPS
#46FORMULATIONS
#47FORMULATIONS COMPRISING CYCLOSPORIN A
#48COMPOSITIONS COMPRISING CYCLOSPORIN
#49DELIVERY SYSTEM FOR USE IN MEDICINE
#50PHARMACEUTICAL COMPOSITIONS
#51SOLID NANOPARTICLE WITH INORGANIC COATING
#52FORTIFIED MICRONUTRIENT SALT FORMULATIONS
#53Particles for Targeted Delivery and Uses in Managing Bleeding or Blood Clotting
#54Muco-adhesive, controlled release formulations of levodopa and/or esters of levodopa and uses thereof
#55IMMEDIATE RELEASE ABUSE-DETERRENT GRANULATED DOSAGE FORMS
#56Implantable device for sustained release of a macromolecular drug compound
#57Implantable device for sustained release of a macromolecular drug compound
#58LOW BURST-RELEASE LIRAGLUTIDE DEPOT SYSTEMS
#59Extended release compositions comprising pyridostigmine
#60PRUSSIAN BLUE NANOPARTICLES FUNCTIONALIZATION WITH LATENCY REVERSING AGENTS AND BROADLY NEUTRALIZING ANTIBODIES, AND APPLICATIONS THEREOF
#61METHODS OF FABRICATING HYPER COMPLIANT POLYMER PARTICLES AND METHODS OF USE AND COMPOSITIONS
#62METHYLPHENIDATE COMPOSITIONS FOR TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER
#63Muco-adhesive, controlled release formulations of levodopa and/or esters of levodopa and uses thereof
#64GRANULAR PHARMACEUTICAL PRODUCT FOR ORAL ADMINISTRATION FROM A PRE-FILLED STRAW AND METHOD OF MANUFACTURING SUCH PHARMACEUTICAL PRODUCT
#65Oral solid cannabinoid oil composition for treating gastrointestinal disorders
#66ESOMEPRAZOLE ORAL PREPARATION AND METHOD FOR PRODUCING THE SAME
#67DOSAGE FORM FOR USE IN TREATING OR PREVENTING OF A DISEASE
#68Particles for targeted delivery and uses in managing bleeding or blood clotting
#69INGESTIBLE MEDICAL DELIVERY DEVICES
#70Hybrid membrane camouflaged nanomedicine loaded with oxidative phosphorylation inhibitor and preparing method thereof
#71Particles Containing a Lipid Matrix Core and Active Ingredient
#72MODIFIED RELEASE ORALLY ADMINISTERED AMINO ACID FORMULATIONS
#73PHARMACEUTICAL GRANULATIONS OF WATER-SOLUBLE ACTIVE PHARMACEUTICAL INGREDIENTS
#74METHODS TO PREPARE DRY POWDERS USING SUSPENSION BASED THIN FILM FREEZING
#75NESTED CELL ENCAPSULATION
#76Pharmaceutical preparation having excellent dissolution properties, containing esomeprazole and sodium bicarbonate
#77NEW DELIVERY SYSTEM FOR FAT SOLUBLE VITAMINS
#78NEW DELIVERY SYSTEM FOR SPECIFIC WATER-SOLUBLE VITAMINS
#79NEW DELIVERY SYSTEM FOR POLYUNSATURATED FATTY ACIDS
#80LIQUID GUAIFENESIN COMPOSITIONS WITH STABLE EXTENDED RELEASE PROFILES
#81Immediate release abuse-deterrent granulated dosage forms
#82Compositions for treatment of attention deficit hyperactivity disorder
#83Compositions for Treatment of Attention Deficit Hyperactivity Disorder
#84Fluid storage media and method of delivering a fluid
#85Extended release compositions comprising pyridostigmine
#86FORMULATIONS FOR ORAL DELIVERY OF ADSORBENTS IN THE GUT
#87FORMULATIONS
#88GRANULE, PREPARATION CONTAINING THE GRANULE, PRODUCTION METHOD OF THE GRANULE, AND PRODUCTION METHOD OF PREPARATION CONTAINING THE GRANULE
#89Enteric coated multiparticulate compositions with a proteinaceous subcoat
#90COMPOSITIONS COMPRISING CYCLOSPORIN
#91Compositions for controlled release of cysteamine and systemic treatment of cysteamine sensitive disorders
#92Coated hollow and evacuated insulation spheres (CEIS)
#93Oral amphetamine composition
#94COMPOSITIONS AND METHODS FOR TREATING MULTIPLE SCLEROSIS
#95Biomass-based encapsulating material for protection of probiotic activity and an encapsulating method
#96Pharmaceutical granulations of water-soluble active pharmaceutical ingredients
#97FORMULATIONS COMPRISING CYCLOSPORIN A
#98ESCALATING DOSING REGIMEN FOR EFFECTING WEIGHT LOSS AND TREATING OBESITY
#99Sustained release injectable formulation containing a poly L lactic acid filler and a hyaluronic acid filler conjugate and a method for preparing the same
#100Minimizing agglomeration, aeration, and preserving the coating of pharmaceutical compositions comprising ibuprofen
#101COMPOSITION COMPRISING OIL DROPS
#102Muco-adhesive, controlled release formulations of levodopa and/or esters of levodopa and uses thereof
#103Nanostructure lipid system
#104A PHARMACEUTICAL FORMULATION FOR ORAL ADMINISTRATION WITH IMPROVED CONTENT UNIFORMITY COMPRISING SUSTAINED-RELEASE PELLETS CONTAINING TAMSULOSIN HYDROCHLORIDE
#105LOADABLE POLYMERIC PARTICLES FOR THERAPEUTIC AND/OR DIAGNOSTIC APPLICATIONS AND METHODS OF PREPARING AND USING THE SAME
#106SHELLAC MICROCAPSULE FORMULATIONS AND COMPOSITIONS FOR TOPICAL INTESTINAL DELIVERY OF VITAMIN B3
#107METHYLPHENIDATE COMPOSITIONS FOR TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER
#108COMPOSITION COMPRISING A THERAPEUTIC AGENT AND A RESPIRATORY STIMULANT AND METHODS FOR THE USE THEREOF
#109Formulations and Pharmacokinetics of Deuterated Benzoquinoline Inhibitors of Vesicular Monoamine Transporter 2
#110Cationic materials and formulations for drug delivery
#111MULTIPARTICULATE INCLUDING PHARMACEUTICAL OR PROBIOTIC ACTIVE INGREDIENTS FOR DELIVERY VIA A SHELF STABLE LIQUID DOSAGE FORM
#112Carrier composition for eye drops and pharmaceutical composition including the same
#113Oral solid cannabinoid oil composition for treating gastrointestinal disorders
#114PHARMACEUTICAL OR NUTRACEUTICAL COMPOSITION WITH RESISTANCE AGAINST THE INFLUENCE OF ETHANOL
#115Pharmaceutical compositions comprising activated carbon
#116Pharmaceutical composition of Tamsulosin and Dutasteride
#117POWDER COATING COMPOSITIONS FOR COATING PHARMACEUTICAL PELLETS
#118Delivery system
#119PROCESS FOR THE MANUFACTURE OF PHARMACEUTICAL COMPOSITIONS
#120COMPOSITIONS AND METHODS FOR MASKING THE TASTE OF DRUGS
#121FORMULATION HAVING IMPROVED PH-DEPENDENT DRUG-RELEASE CHARACTERISTICS CONTAINING ESOMEPRAZOLE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF
#122Implantable particles and related methods
#123Encapsulated antimicrobials and related methods of treatment
#124PACKAGED MODIFIED RELEASE GAMMA-HYDROXYBUTYRATE FORMULATIONS HAVING IMPROVED STABILITY
#125Encapsulated antimicrobials and related methods of treatment
#126Muco-adhesive, controlled release formulations of levodopa and/or esters of levodopa and uses thereof
#127Solid nanoparticle with inorganic coating
#128Modified release formulations of 2-[3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4-methyl-4-[4-(oxetan-3-yl)piperazin-1-yl]pent-2-enenitrile
#129Compositions for treatment of attention deficit hyperactivity disorder
#130Immediate release abuse-deterrent granulated dosage forms
#131Methods and Compositions Particularly for Treatment of Attention Deficit Disorder
#132Compositions for treatment of attention deficit hyperactivity disorder
#133Extended release compositions comprising pyridostigmine
#134Gastrointestinal site-specific oral vaccination formulations active on the ileum and appendix
#135Method for preparing particles comprising metal oxide coating and particles with metal oxide coating
#136Minimizing agglomeration, aeration, and preserving the coating of pharmaceutical compositions comprising ibuprofen
#137METHOD FOR PREPARING PARTICLES COMPRISING METAL OXIDE COATING AND PARTICLES WITH METAL OXIDE COATING
#138PACKAGED MODIFIED RELEASE GAMMA-HYDROXYBUTYRATE FORMULATIONS HAVING IMPROVED STABILITY
#139Delivery system
#140MULTILAYERED PHARMACEUTICALLY ACTIVE COMPOUND-RELEASING MICROPARTICLES IN A LIQUID DOSAGE FORM
#141Particles for targeted delivery and uses in managing bleeding or blood clotting
#142Ingestible medical delivery devices
#143Formulations and pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2
#144LAYERED SUSTAINED-RELEASE MICROBEADS AND METHODS OF MAKING THE SAME
#145Minimizing agglomeration, aeration, and preserving the coating of pharmaceutical compositions comprising ibuprofen
#146METHOD FOR PREPARING A SOLID DOSAGE FORM COMPRISING ANTIBODIES BY WET GRANULATION, EXTRUSION AND SPHERONIZATION
#147System for delivery of medical components to the lungs
#148Formulations and pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2
#149Delayed release pharmaceutical composition of pantoprazole and process for formulation thereof
#150Multiparticulate L-carnitine compositions and related methods
#151Muco-adhesive, controlled release formulations of levodopa and/or esters of levodopa and uses thereof
#152Modified release composition of orlistat and acarbose for the treatment of obesity and related metabolic disorders
#153Compositions for treatment of attention deficit hyperactivity disorder
#154Compositions for treatment of attention deficit hyperactivity disorder
#155ESCALATING DOSING REGIMEN FOR EFFECTING WEIGHT LOSS AND TREATING OBESITY
#156MRI-DETECTABLE MULTILAYER MICROCAPSULES FOR ULTRASOUND-TRIGGERED DELIVERY OF PHARMACOLOGICALLY ACTIVE AGENTS
#157COMPOSITIONS FOR USE IN THE TREATMENT OF ULCERATIVE COLITIS
#158Formulations of homotaurines and salts thereof
#159Process for preparation of an enteric coated granulate comprising dimethyl fumarate
#160Particles comprising a shell with RNA
#161Compositions and methods for treating multiple sclerosis
#162Methods and compositions particularly for treatment of attention deficit disorder
#163CATIONIC MATERIALS AND FORMULATIONS FOR DRUG DELIVERY
#164Solid nanoparticle with inorganic coating
#165Timed, pulsatile release systems
#166Extended release pharmaceutical composition of clozapine
#167Oral cholestyramine formulation and use thereof
#168Layered particles and processes thereof
#169PHARMACEUTICAL CYCLOSPORIN COMPOSITIONS
#170ORAL PHARMACEUTICAL COMPOSITION
#171Muco-adhesive, controlled release formulations of levodopa and/or esters of levodopa and uses thereof
#172Composition for controlled release of physiologically active substances and process for its preparation
#173GASTRORESISTANT PHARMACEUTICAL FORMULATIONS CONTAINING RIFAXIMIN
#174IMPROVED COMPOSITIONS AND METHODS FOR REDUCING OVERDOSE
#175FORMULATIONS
#176MINERAL COATED MICROPARTICLES FOR SUSTAINED DELIVERY OF STEROIDS
#177Implantable device for sustained release of a macromolecular drug compound
#178Implantable device for sustained release of a macromolecular drug compound
#179ESCALATING DOSING REGIMEN FOR EFFECTING WEIGHT LOSS AND TREATING OBESITY
#180Method Of Manufacturing Fine Particles Suitable For Orally Disintegrating Pharmaceutical Dosage Forms
#181PHARMACEUTICAL COMPOSITION
#182Oral amphetamine composition
#183Methods of fabricating hyper compliant polymer particles and methods of use and compositions
#184Pharmaceutical Compositions for the Deterrence and/or Prevention of Abuse
#185Method of making an L-menthol dosage form
#186EXTENDED RELEASE DRUG FORMULATION WITH OVERDOSE PROTECTION AND ABUSE DETERRENCE
#187Reduced permeability microcapsules
#188PHARMACEUTICAL COMPOSITION COMPRISING AN ANTIEMETIC AGENT AND METHOD FOR THE PREPARATION THEREOF
#189Therapeutic targets involved in the progression of nonalcoholic steatohepatitis (NASH)
#190Unit doses for immediate release of GHB or of one of the therapeutically acceptable salts thereof, administered orally, and the use thereof to maintain alcohol abstinence
#191Muco-adhesive, controlled release formulations of levodopa and/or esters of levodopa and uses thereof
#192Formulation having improved pH-dependent drug-release characteristics, containing esomeprazole or pharmaceutically acceptable salt thereof
#193Multiparticulate including pharmaceutical or probiotic active ingredients for delivery via a shelf stable liquid dosage form
#194DELAYED-RELEASE FORMULATIONS, METHODS OF MAKING AND USE THEREOF
#195FORMULATIONS
#196Tamper resistant pharmaceutical formulations
#197METHOD OF PREPARING PHARMACEUTICAL MICROSPHERE
#198COMPOSITION FOR THE TREATMENT OF DISEASE
#199Immediate release abuse-deterrent granulated dosage forms
#200Compositions for treatment of attention deficit hyperactivity disorder
#201Delayed release pharmaceutical composition of pantoprazole and process for formulation thereof
#202Controlled Release Dosage Form for Once Daily Administration of Dimethyl Fumarate
#203Formulations And Pharmacokinetics Of Deuterated Benzoquinoline Inhibitors Of Vesicular Monoamine Transporter 2
#204HYPERAMMONEMIA THERAPY FOR CHILDREN SUFFERING FROM UREA CYCLE DISORDERS
#205Timed, pulsatile release systems
#206Cholestyramine granules, oral cholestyramine formulations and use thereof
#207Compositions for controlled release of cysteamine and systemic treatment of cysteamine sensitive disorders
#208Methods of treatment of attention deficit hyperactivity disorder
#209OVERDOSE PROTECTION AND ABUSE DETERRENT IMMEDIATE RELEASE DRUG FORMULATION
#210Sprinkle formulations of acamprosate
#211Ingestible medical delivery devices
#212Enteric coated oral pharmaceutical preparation comprising dimethyl fumarate
#213Premixture and pharmaceutical composition for the oral administration of memantine as a permanent suspension or one prepared prior to administering to the patient and optionally by enteral feeding tube and corresponding procedures
#214MULTILAYERED PHARMACEUTICALLY ACTIVE COMPOUND-RELEASING MICROPARTICLES IN A LIQUID DOSAGE FORM
#215Controlled Release Dosage Form for Once Daily Administration of Dimethyl Fumarate
#216Stable orally disintegrating pharmaceutical compositions
#217PULSATILE RELEASE PHARMACEUTICAL COMPOSITION COMPRISING NAFTAZONE OR ONE OF ITS SALTS
#218Layered sustained-release microbeads and methods of making the same
#219Multiparticulate L-carnitine compositions and related methods
#220Formulations for oral delivery of adsorbents in the gut
#221FORMULATIONS COMPRISING CYCLOSPORIN A
#222Oral cholestyramine formulation and use thereof
#223Oral cholestyramine formulation and use thereof
#224Oral cholestyramine formulation and use thereof
#225Multiphasic particles fabricated by wettability engendered templated self-assembly (WETS) methods
#226Pharmaceutical formulation for bedwetting and method of use thereof
#227Core-shell composite material
#228Modified release orally administered amino acid formulations
#229Cationic materials and formulations for drug delivery
#230Oral amphetamine composition
#231Composition comprising a therapeutic agent and a respiratory stimulant and methods for the use thereof
#232Particles comprising a shell with RNA
#233COMPOSITION COMPRISING OIL DROPS
#234Oral cholestyramine formulation and use thereof
#235Compositions and methods for treating multiple sclerosis
#236NEW DODECAPEPTIDES AND MICROCAPSULES FUNCTIONALISED WITH THEM TARGETED TO FIBROBLASTS
#237Multi-encapsulated formulations made with oxidized cellulose
#238Solid nanoparticle with inorganic coating
#239PHARMACEUTICAL COMPOSITIONS COMPRISING 40-O-(2-HYDROXY)ETHYL-RAPAMYCIN
#240COMPOSITIONS FOR ILEO-JEJUNAL DRUG DELIVERY
#241Modified release orally administered amino acid formulations
#242EXTENDED RELEASE PHARMACEUTICAL COMPOSITION OF MIXED AMPHETAMINES
#243Compositions comprising Cyclosporin
#244Pharmaceutical or nutraceutical composition with resistance against the influence of ethanol
#245Rivastigmine-containing sustained-release pharmaceutical composition
#246COMPOSITIONS AND METHODS FOR ADMINISTRATION TO SUBJECTS WITH DYSPHAGIA
#247Solid nanoparticle with inorganic coating
#248Methods of treating attention deficit hyperactivity disorder
#249SITE SPECIFIC DOSING OF A BTK INHIBITOR
#250USE OF MTOR INHIBITORS TO PREVENT AND REGRESS EDHESIONS AND FIBROSIS
#251Controlled release formulations
#252Formulations and Methods for Attenuating Respiratory Depression Induced by Opioid Overdose
#253Controlled release from particles encapsulated by molecular layer deposition
#254Enteric Film Coating Compositions, Method of Coating, and Coated Forms
#255Co-encapsulation of live cells with oxygen-generating particles
#256Nanoparticle
#257COMPOSITION FOR THE TREATMENT OF DISEASE
#258Preparation of nanoparticles-releasing enteric microparticles
#259Pharmaceutical or nutraceutical composition with resistance against the influence of ethanol
#260Formulations for oral delivery of adsorbents in the gut
#261Methods of Treatment of Attention Deficit Hyperactivity Disorder
#262MODIFIED RELEASE ABUSE DETERRENT DOSAGE FORMS
#263Drug-containing particulate composition with cationic agent, associated medical devices, and methods for treatment
#264INJECTABLE MICROSPHERES
#265Multiparticulate L-menthol formulations and related methods
#266Pharmaceutical cyclosporin compositions
#267Pharmaceutical composition of rosuvastatin calcium
#268Oral cholestyramine formulation and use thereof
#269Oral cholestyramine formulation and use thereof
#270Fortified micronutrient salt formulations
#271Oral pharmaceutical composition
#272Method of manufacturing fine particles suitable for orally disintegrating pharmaceutical dosage forms
#273Loadable polymeric particles for therapeutic and/or diagnostic applications and methods of preparing and using the same
#274SOLID DOSAGE FORM COMPRISING PROTON PUMP INHIBITOR AND SUSPENSION MADE THEREOF
#275Multiple-layer immune barrier for donor cells
#276FORMULATION FOR ORAL ADMINISTRATION CONTAINING MESALAZINE
#277Immediate release abuse-deterrent granulated dosage forms
#278CONTROLLED RELEASE FORMULATIONS HAVING RAPID ONSET AND RAPID DECLINE OF EFFECTIVE PLASMA DRUG CONCENTRATIONS
#279Co-encapsulation of live cells with oxygen-generating particles
#280Timed, pulsatile release systems
#281Compositions for treatment of attention deficit hyperactivity disorder
#282Methods of preparing oral controlled release formulations
#283Methods of treating attention deficit hyperactivity disorder
#284Compositions for treatment of attention deficit hyperactivity disorder
#285EXTENDED-RELEASE DOSAGE FORM
#286Stem cells having thin multilayer structure
#287Pharmaceutical composition containing nicotinic acid and/or nicotinamide for beneficially influencing blood lipid levels by modifying the intestinal microbiota
#288Extended release pharmaceutical compositions
#289Composition comprising a therapeutic agent and a respiratory stimulant and methods for the use thereof
#290Oral formulations Mimetic of Roux-en-Y gastric bypass actions on the ileal brake; Compositions, Methods of Treatment, Diagnostics and Systems for treatment of metabolic syndrome manifestations including insulin resistance, fatty liver disease, hyperlipidemia, and T2D
#291Nanoparticle drug delivery
#292Composition and method for improving stability and extending shelf life of probiotic bacteria and food products thereof
#293Method of making water soluble injectable calcium polyphosphate gels
#294ENCAPSULATED CELLS FOR TREATING LOW TESTOSTERONE IN MALE SUBJECTS
#295Pharmaceutical or nutraceutical composition with sustained release characteristic and with resistance against the influence of ethanol
#296Abuse-resistant drug formulations with built-in overdose protection
#297Cationic materials and formulations for drug delivery
#298Multimicroparticulate pharmaceutical forms foe oral administration
#299COMPOSITIONS FOR USE IN THE TREATMENT OF ULCERATIVE COLITIS
#300Enteric coated multiparticulate controlled release peppermint oil composition and related methods